Moderate

Chronic hepatitis C treatment

HCV cure · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic hepatitis C is curable in over 95% with 8-12 weeks of pangenotypic direct-acting antiviral therapy. Treatment is recommended for nearly all infected people, with cure defined as sustained virological response 12 weeks after completion.

Red flags

  • Decompensated cirrhosis (avoid protease-inhibitor regimens)
  • Hepatitis B co-infection (reactivation risk)
  • Significant drug interactions (e.g. amiodarone with sofosbuvir)
  • Signs of hepatocellular carcinoma
  • Treatment failure after prior DAA course

Assessment

Differential diagnosis

  • Spontaneously cleared infection (antibody positive, RNA negative)
  • Acute versus chronic hepatitis C
  • HIV or hepatitis B co-infection
  • Decompensated cirrhosis (alters regimen)
  • Other causes of transaminitis

Investigations

  • Hepatitis C antibody then HCV RNA (viral load) to confirm active infection
  • HCV genotype (optional with pangenotypic regimens)
  • Liver fibrosis staging (elastography or non-invasive score)
  • HIV and hepatitis B serology
  • Liver and renal function, FBC
  • Pregnancy test and medication interaction review

Management

  • Confirm active infection with detectable HCV RNA
  • Assess fibrosis/cirrhosis status (determines duration and regimen)
  • Screen for HIV and hepatitis B co-infection; prophylax HBV reactivation if HBsAg positive
  • Review concomitant drugs for interactions (statins, acid suppression, anticonvulsants)
  • Select a pangenotypic direct-acting antiviral regimen by cirrhosis status
  • Counsel on adherence, reinfection risk and harm reduction
  • Treat for 8-12 weeks (longer/with ribavirin in decompensated disease)
  • Check adherence during therapy
  • Confirm cure with HCV RNA at 12 weeks post-treatment (SVR12)
  • Continue HCC surveillance in those with cirrhosis despite cure
  • Offer reinfection screening in ongoing-risk individuals
  • Vaccinate against hepatitis A and B

Drugs & doses

Sofosbuvir/velpatasvir 400/100 mg PO once daily for 12 weeks
Glecaprevir/pibrentasvir 300/120 mg PO once daily with food for 8 weeks (no/compensated cirrhosis)
Sofosbuvir/velpatasvir/voxilaprevir 400/100/100 mg PO once daily for 12 weeks (prior DAA failure)
Ribavirin weight-based (1000-1200 mg/day PO) added in decompensated cirrhosis

Disposition

Outpatient hepatology/ID or community HCV service; cure confirmed then discharge with surveillance if cirrhotic.

Complications & pitfalls

  • Treatment failure/resistance (rare)
  • Hepatitis B reactivation during therapy
  • Persisting cirrhosis with ongoing HCC risk
  • Reinfection in ongoing-risk groups
  • Drug interaction adverse events

Exam pearls

  • Pangenotypic regimens have largely removed the need for genotyping
  • Cure does not reverse established cirrhosis; continue HCC surveillance
  • Avoid sofosbuvir with amiodarone (bradycardia risk)
  • Short 8-week courses suit most without cirrhosis
  • Antibody persists after cure; monitor RNA for reinfection

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.